{"id":35559,"date":"2025-06-19T14:33:35","date_gmt":"2025-06-19T06:33:35","guid":{"rendered":"https:\/\/flcube.com\/?p=35559"},"modified":"2025-06-19T14:33:36","modified_gmt":"2025-06-19T06:33:36","slug":"gileads-yeztugo-approved-by-fda-as-first-six-monthly-injectable-hiv-prep","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35559","title":{"rendered":"Gilead’s Yeztugo Approved by FDA as First Six-Monthly Injectable HIV PrEP"},"content":{"rendered":"\n

US-based Gilead Sciences, Inc. (NASDAQ: GILD<\/a>) announced that it has received market approval from the US Food and Drug Administration (FDA) for its Yeztugo (lenacapavir). The injectable HIV-1 capsid inhibitor can now be used as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg. This makes it the first and only HIV prevention regimen administered via subcutaneous injection every six months.<\/p>\n\n\n\n

Mechanism of Action<\/strong>
Lenacapavir’s multi-stage mechanism of action sets it apart from other approved antiviral drugs. While most antivirals target a single stage of viral replication, lenacapavir is designed to inhibit multiple phases of the HIV lifecycle. No cross-resistance has been observed in vitro with existing drug classes.<\/p>\n\n\n\n

Clinical Trial Results<\/strong>
The FDA approval is based on results from the global pivotal Phase III PURPOSE 1 and PURPOSE 2 studies. PURPOSE 1, conducted in sub-Saharan Africa, enrolled HIV-negative women aged 16\u201325. The trial showed zero HIV infections among 2,134 participants receiving twice-yearly Yeztugo, demonstrating 100% efficacy and superiority over daily oral Truvada in preventing HIV. PURPOSE 2 further confirmed Yeztugo\u2019s efficacy and safety in a broader high-risk population.<\/p>\n\n\n\n

Global Expansion<\/strong>
Gilead has filed for marketing approval in multiple regions, including Europe, Australia, Brazil, Canada, and South Africa, and plans to pursue registrations in additional FDA-reliant countries.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that it has received market approval from the…<\/p>\n","protected":false},"author":1,"featured_media":35561,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[226,631,1025,15],"class_list":["post-35559","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-gilead-sciences","tag-hiv-aids-care","tag-nasdaq-gild","tag-product-approvals"],"yoast_head":"\nGilead's Yeztugo Approved by FDA as First Six-Monthly Injectable HIV PrEP - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that it has received market approval from the US Food and Drug Administration (FDA) for its Yeztugo (lenacapavir). The injectable HIV-1 capsid inhibitor can now be used as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg. This makes it the first and only HIV prevention regimen administered via subcutaneous injection every six months.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35559\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead's Yeztugo Approved by FDA as First Six-Monthly Injectable HIV PrEP\" \/>\n<meta property=\"og:description\" content=\"US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that it has received market approval from the US Food and Drug Administration (FDA) for its Yeztugo (lenacapavir). The injectable HIV-1 capsid inhibitor can now be used as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg. This makes it the first and only HIV prevention regimen administered via subcutaneous injection every six months.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35559\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-19T06:33:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-19T06:33:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1902.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35559#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35559\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gilead’s Yeztugo Approved by FDA as First Six-Monthly Injectable HIV PrEP\",\"datePublished\":\"2025-06-19T06:33:35+00:00\",\"dateModified\":\"2025-06-19T06:33:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35559\"},\"wordCount\":228,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35559#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1902.webp\",\"keywords\":[\"Gilead Sciences\",\"HIV \\\/ AIDS care\",\"NASDAQ: GILD\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35559#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35559\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35559\",\"name\":\"Gilead's Yeztugo Approved by FDA as First Six-Monthly Injectable HIV PrEP - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35559#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35559#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1902.webp\",\"datePublished\":\"2025-06-19T06:33:35+00:00\",\"dateModified\":\"2025-06-19T06:33:36+00:00\",\"description\":\"US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that it has received market approval from the US Food and Drug Administration (FDA) for its Yeztugo (lenacapavir). The injectable HIV-1 capsid inhibitor can now be used as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg. This makes it the first and only HIV prevention regimen administered via subcutaneous injection every six months.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35559#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35559\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35559#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1902.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1902.webp\",\"width\":1080,\"height\":608,\"caption\":\"Gilead's Yeztugo Approved by FDA as First Six-Monthly Injectable HIV PrEP\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35559#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead’s Yeztugo Approved by FDA as First Six-Monthly Injectable HIV PrEP\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead's Yeztugo Approved by FDA as First Six-Monthly Injectable HIV PrEP - Insight, China's Pharmaceutical Industry","description":"US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that it has received market approval from the US Food and Drug Administration (FDA) for its Yeztugo (lenacapavir). The injectable HIV-1 capsid inhibitor can now be used as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg. This makes it the first and only HIV prevention regimen administered via subcutaneous injection every six months.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35559","og_locale":"en_US","og_type":"article","og_title":"Gilead's Yeztugo Approved by FDA as First Six-Monthly Injectable HIV PrEP","og_description":"US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that it has received market approval from the US Food and Drug Administration (FDA) for its Yeztugo (lenacapavir). The injectable HIV-1 capsid inhibitor can now be used as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg. This makes it the first and only HIV prevention regimen administered via subcutaneous injection every six months.","og_url":"https:\/\/flcube.com\/?p=35559","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-19T06:33:35+00:00","article_modified_time":"2025-06-19T06:33:36+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1902.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35559#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35559"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gilead’s Yeztugo Approved by FDA as First Six-Monthly Injectable HIV PrEP","datePublished":"2025-06-19T06:33:35+00:00","dateModified":"2025-06-19T06:33:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35559"},"wordCount":228,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=35559#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1902.webp","keywords":["Gilead Sciences","HIV \/ AIDS care","NASDAQ: GILD","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35559#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35559","url":"https:\/\/flcube.com\/?p=35559","name":"Gilead's Yeztugo Approved by FDA as First Six-Monthly Injectable HIV PrEP - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=35559#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=35559#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1902.webp","datePublished":"2025-06-19T06:33:35+00:00","dateModified":"2025-06-19T06:33:36+00:00","description":"US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that it has received market approval from the US Food and Drug Administration (FDA) for its Yeztugo (lenacapavir). The injectable HIV-1 capsid inhibitor can now be used as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg. This makes it the first and only HIV prevention regimen administered via subcutaneous injection every six months.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35559#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35559"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=35559#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1902.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1902.webp","width":1080,"height":608,"caption":"Gilead's Yeztugo Approved by FDA as First Six-Monthly Injectable HIV PrEP"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35559#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gilead’s Yeztugo Approved by FDA as First Six-Monthly Injectable HIV PrEP"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1902.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35559","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35559"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35559\/revisions"}],"predecessor-version":[{"id":35562,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35559\/revisions\/35562"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/35561"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35559"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35559"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35559"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}